Literature DB >> 29312776

Case report: dermatomyositis associated with lung cancer with heterogeneous morphology.

Yin-Yin Qin1, Cheng-Zhi Zhou1, Zheng Zhu1, Wei-Jie Guan1, Xin-Qing Lin1, Chun-Li Liu1, Yu-Ming Zhou1, Hua Wu1, Ying-Ying Gu1, De-Hua Zhang1, Ming Ou-Yang1, Nan-Shan Zhong1, Shi-Yue Li1.   

Abstract

Dermatomyositis (DM) complicated with non-small cell lung cancer (NSCLC) is not rare, and could rapidly develop into severe lung cancer [performance-status score (PS) between 2 and 4]. Moreover, tumor has remarkable heterogeneity, and it is not possible to properly target treatments in cases of relapse without knowing pathological diagnosis. We retrospectively analyzed the diagnosis and treatment of a patient with DM complicated with NSCLC, which developed into severe lung cancer with heterogeneity of the tumor during chemotherapy. In this report, we addressed that in patients with severe lung cancer, both the cancer and factors associated with exacerbation should be simultaneously managed to reduce the PS score and avoid unnecessary delay. A second biopsy is important for proper management of the tumor with heterogeneity.

Entities:  

Keywords:  Dermatomyositis (DM); clinical management; non-small cell lung cancer (NSCLC); respiratory symptoms; second biopsy; severe lung cancer

Year:  2017        PMID: 29312776      PMCID: PMC5756961          DOI: 10.21037/jtd.2017.11.107

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  11 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China.

Authors:  Dongying Chen; Shiwen Yuan; Xiangni Wu; Hao Li; Qian Qiu; Zhongping Zhan; Yujin Ye; Fan Lian; Liuqin Liang; Hanshi Xu; Xiuyan Yang
Journal:  Clin Exp Rheumatol       Date:  2014-07-28       Impact factor: 4.473

3.  Paraneoplastic polymyositis associated with squamous cell carcinoma of the lung.

Authors:  Mikhail Gabrilovich; Mohammad Raza; Stephen Dolan; Tasleem Raza
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

4.  Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

Authors:  C L Hill; Y Zhang; B Sigurgeirsson; E Pukkala; L Mellemkjaer; A Airio; S R Evans; D T Felson
Journal:  Lancet       Date:  2001-01-13       Impact factor: 79.321

5.  Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study.

Authors:  Zaixing Yang; Feng Lin; Baodong Qin; Yan Liang; Renqian Zhong
Journal:  J Rheumatol       Date:  2014-12-01       Impact factor: 4.666

6.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

7.  Clonal competition with alternating dominance in multiple myeloma.

Authors:  Jonathan J Keats; Marta Chesi; Jan B Egan; Victoria M Garbitt; Stephen E Palmer; Esteban Braggio; Scott Van Wier; Patrick R Blackburn; Angela S Baker; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John D Carpten; Michael Barrett; Rafael Fonseca; A Keith Stewart; P Leif Bergsagel
Journal:  Blood       Date:  2012-04-12       Impact factor: 22.113

8.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

Review 9.  Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments.

Authors:  Antti P Jekunen
Journal:  J Oncol       Date:  2015-01-29       Impact factor: 4.375

10.  Stem-like cancer cells are inducible by increasing genomic instability in cancer cells.

Authors:  Yi Liang; Zhendong Zhong; Yijun Huang; Wen Deng; Junxia Cao; George Tsao; Quentin Liu; Duanqing Pei; Tiebang Kang; Yi-Xin Zeng
Journal:  J Biol Chem       Date:  2009-12-09       Impact factor: 5.157

View more
  1 in total

1.  Randomized phase III study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease.

Authors:  Guoying Gao; Chengzhi Zhou; Yucheng Huang; Ziying Hong; Pei Yu; Ying Chen; Jiabo Gao; Kening Zhang; Zhanhong Xie; Jiexia Zhang; Shiyue Li; Nagata Masashi; Yinyin Qin
Journal:  Transl Lung Cancer Res       Date:  2021-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.